Comment on "Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk"
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Rajasimhan S, Pamuk O, Katz J Drugs Aging. 2021; 38(6):539-541.
PMID: 33871805 PMC: 8211588. DOI: 10.1007/s40266-021-00856-4.
References
1.
Rajasimhan S, Pamuk O, Katz J
. Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk. Drugs Aging. 2020; 37(8):551-558.
PMC: 7387323.
DOI: 10.1007/s40266-020-00775-w.
View
2.
Keohane C, McLornan D, Sanchez K, Connor C, Radia D, Harrison C
. The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms. Haematologica. 2015; 100(9):e348-50.
PMC: 4800696.
DOI: 10.3324/haematol.2015.128918.
View
3.
Ardito F, Giuliani M, Perrone D, Troiano G, Lo Muzio L
. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). Int J Mol Med. 2017; 40(2):271-280.
PMC: 5500920.
DOI: 10.3892/ijmm.2017.3036.
View
4.
McInnes I, Byers N, Higgs R, Lee J, Macias W, Na S
. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019; 21(1):183.
PMC: 6679539.
DOI: 10.1186/s13075-019-1964-1.
View
5.
Masciulli A, Ferrari A, Carobbio A, Ghirardi A, Barbui T
. Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2020; 4(2):380-386.
PMC: 6988397.
DOI: 10.1182/bloodadvances.2019001158.
View